))
AI: How to think differently
Manage episode 331655538 series 2994360
Contenu fourni par Adam.Roberts@ttp.com and TTP plc. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Adam.Roberts@ttp.com and TTP plc ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
The hunt to discover new pharmaceuticals in areas of high unmet need can be complex, time-consuming, and costly. For every life saving therapy that hits the market, thousands and even millions of candidate drugs are rejected. A new technology could be changing the way we home in on the most effective therapy: AI. The use of AI in drug discovery - whether through mining research or in highlighting new experimental insight - is one of the most exciting new sectors in the field. But how does it really work? What are the conditions needed to implement it? Is it really anything more than just a useful tool? In this episode of Invent: Life Sciences from TTP, we take a look at this fascinating new frontier for drug discovery.
Find out more on this week's episode of Invent: Life Sciences from TTP.
This Week's Guests
Dr. Sarah Morrow
Sarah is a Life Sciences Consultant at TTP, joining in 2020 after getting her PhD specialising in Organic Chemistry from the University of Oxford. Sarah brings a chemist’s perspective on the challenges encountered within drug discovery, as well as focusing on the technology - both hardware and software - that could enable and accelerate the field.
https://www.linkedin.com/in/sarah-morrow-841719146/
Aaron Morris
Aaron Morris is the CEO and co-founder of PostEra, a company building an end-to-end medicinal chemistry platform to advance drug discovery, using machine learning and AI to do so. After seeing the limiting nature of drug discovery on bio tech companies and pharma, Aaron set up PostEra to come in at this early stage and work alongside them to reduce these issues, and to serve the world's ever expanding community of drug hunters.
https://postera.ai/
Dr. Andreas Bender
Andreas Bender is a Professor of Life Sciences informatics interested in developing new life science data analysis methods for their application in drug discovery. After over a decade at Cambridge University working in molecular informatics, Andreas is now the CSO at Terra Lumina, a company building the world’s largest dataset of natural compounds, using AI that unlocks the connection between nature’s small molecules and the human body.
https://terralumina.bio/
The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/
23 episodes
Partager
